14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:RXII
Delisted

RXI Pharmaceuticals Corporation Fund Price (Quote)

$0.82
+0 (+0%)
At Close: Dec 08, 2023

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 8th Dec 2023 RXII stock ended at $0.82. During the day the stock fluctuated 0% from a day low at $0.82 to a day high of $0.82.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical RXI Pharmaceuticals Corporation prices

Date Open High Low Close Volume
Mar 11, 2016 $30.00 $30.00 $28.00 $28.00 2 635
Mar 10, 2016 $32.00 $32.00 $29.00 $31.00 972
Mar 09, 2016 $31.00 $31.00 $29.00 $29.00 655
Mar 08, 2016 $30.00 $32.00 $28.00 $30.00 2 923
Mar 07, 2016 $30.00 $31.00 $29.00 $30.00 2 416
Mar 04, 2016 $30.00 $31.00 $29.00 $29.00 1 867
Mar 03, 2016 $30.00 $30.00 $28.00 $28.00 1 189
Mar 02, 2016 $28.00 $30.00 $28.00 $28.00 1 557
Mar 01, 2016 $28.00 $28.00 $26.00 $28.00 8 191
Feb 29, 2016 $29.00 $29.00 $28.00 $28.00 784
Feb 26, 2016 $29.00 $31.00 $28.00 $29.00 3 790
Feb 25, 2016 $29.00 $31.00 $28.00 $30.00 1 836
Feb 24, 2016 $29.00 $31.00 $29.00 $30.00 629
Feb 23, 2016 $29.00 $32.00 $29.00 $30.00 1 318
Feb 22, 2016 $30.00 $31.00 $30.00 $31.00 838
Feb 19, 2016 $29.00 $32.00 $29.00 $30.00 1 333
Feb 18, 2016 $30.00 $31.00 $29.00 $30.00 623
Feb 17, 2016 $30.00 $31.00 $29.00 $30.00 2 424
Feb 16, 2016 $30.00 $31.00 $29.00 $30.00 2 002
Feb 12, 2016 $30.00 $30.00 $28.00 $28.00 1 683
Feb 11, 2016 $28.00 $30.00 $28.00 $28.00 1 026
Feb 10, 2016 $31.00 $31.00 $28.00 $29.00 756
Feb 09, 2016 $30.00 $31.00 $28.00 $28.00 960
Feb 08, 2016 $30.00 $31.00 $28.00 $30.00 1 554
Feb 05, 2016 $30.00 $31.00 $28.00 $29.00 898
Click to get the best stock tips daily for free!

About RXI Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation, a clinical-stage RNAi company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs include RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma... RXII Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT